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Abstract
Background: Schistosomiasis and opisthorchiasis are of public health importance in Southeast Asia. Praziquantel (PZQ) is
the drug of choice for morbidity control but few dose comparisons have been made.
Methodology: Ninety-three schoolchildren were enrolled in an area of Lao PDR where Schistosoma mekongi and
Opisthorchis viverrini coexist for a PZQ dose-comparison trial. Prevalence and intensity of infections were determined by a
rigorous diagnostic effort (3 stool specimens, each examined with triplicate Kato-Katz) before and 28–30 days after
treatment. Ninety children with full baseline data were randomized to receive PZQ: the 40 mg/kg standard single dose
(n= 45) or a 75 mg/kg total dose (50 mg/kg+25 mg/kg, 4 hours apart; n= 45). Adverse events were assessed at 3 and
24 hours posttreatment.
Principal Findings: Baseline infection prevalence of S. mekongi and O. viverrini were 87.8% and 98.9%, respectively. S.
mekongi cure rates were 75.0% (95% confidence interval (CI): 56.6–88.5%) and 80.8% (95% CI: 60.6–93.4%) for 40 mg/kg and
75 mg/kg PZQ, respectively (P= 0.60). O. viverrini cure rates were significantly different at 71.4% (95% CI: 53.4–84.4%) and
96.6% (95% CI: not defined), respectively (P= 0.009). Egg reduction rates (ERRs) against O. viverrini were very high for both
doses (.99%), but slightly lower for S. mekongi at 40 mg/kg (96.4% vs. 98.1%) and not influenced by increasing diagnostic
effort. O. viverrini cure rates would have been overestimated and no statistical difference between doses found if efficacy
was based on a minimum sampling effort (single Kato-Katz before and after treatment). Adverse events were common
(96%), mainly mild with no significant differences between the two treatment groups.
Conclusions/Significance: Cure rate from the 75 mg/kg PZQ dose was more efficacious than 40 mg/kg against O. viverrini
but not against S. mekongi infections, while ERRs were similar for both doses.
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Introduction
Schistosomiasis, food-borne trematodiasis, and soil-transmitted
helminthiasis are neglected tropical diseases that are of considerable
public health relevance in Southeast Asia [1]. In Lao People’s
Democratic Republic (Lao PDR), approximately 80,000 individuals
are at risk for schistosomiasis mekongi, 2 million individuals are at
risk for food-borne trematodiasis (particularly opisthorchiasis), and
1 million school-aged children are at risk for soil-transmitted
helminthiasis [1]. Praziquantel (PZQ) is the current drug of choice
in the treatment of schistosomiasis and most of the food-borne
trematode infections [1]. Deworming programs against schistoso-
miasis aim at morbidity control [2]. The World Health Organiza-
tion (WHO) recommends a standard single dose of oral PZQ
between 40 and 60 mg/kg for both schistosomiasis and food-borne
trematodiasis [1,2]. In Lao PDR, a single dose of 40 mg/kg PZQ is
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recommended for mass treatment of schistosomiasis and opisthor-
chiasis [3]. For individual treatment, the PZQ dose to treat
Opisthorchis viverrini infection is a total dose of 75 mg/kg divided into
three doses [4].
PZQ is known to be effective against all six Schistosoma species
causing disease in humans. However there have been just two
small published clinical trials on PZQ cure rates against Schistosoma
mekongi [5,6]. Both were non-randomized studies involving
individuals relocated to non-endemic areas and given 60 mg/kg
PZQ divided into two or three doses. To our knowledge, a
controlled trial to treat S. mekongi using 40 mg/kg, the recom-
mended dose for mass treatment in Lao PDR, and any com-
parison between different PZQ doses for superiority has so far not
been undertaken.
Several clinical trials have assessed PZQ efficacy against O.
viverrini at the following dosages: single dose of 25, 40, or 50 mg/kg,
or repeated 25 mg/kg doses for a total dose of 50, 75, or 150 mg/kg
[7–13]. However, none has been conducted in Lao PDR, which also
has S. mekongi co-endemic areas, and 40 mg/kg has not been
compared with 75 mg/kg.
Diagnosis of schistosomiasis, opisthorchiasis, and other intestinal
or hepatobiliar helminth infections in epidemiological studies is
commonly based on the detection of parasite eggs in stool spe-
cimens under a microscope. The Kato-Katz technique [14,15] is
the recommended field method [16] and permits estimation of
infection intensity expressed in eggs per gram of feces (EPG). It is a
relatively simple and rapid diagnostic method, but unfortunately, a
single Kato-Katz thick smear has low sensitivity, particularly for
light infections, and hence repeated stool examinations are neces-
sary to improve the sensitivity of this technique [17–20]. This is
especially important after treatment to avoid overestimation of
cure rates. The low sensitivity of a single Kato-Katz thick smear
results from the small amount of stool examined (usually 41.7 mg),
variation in helminth egg excretion over time in the same indi-
vidual, and from variation in egg density within a stool specimen
depending on sampling location, as recognized for Schistosoma
mansoni [19,21,22]. The relative contribution of day-to-day and
intra-specimen variation in fecal egg counts has been investigated
for S. mansoni [19,21] where examination of repeated stool spe-
cimens, rather than examination of multiple Kato-Katz thick
smears derived from a single stool specimen, was shown to be
more appropriate to improve the sensitivity of detecting an
infection [19,22]. While it is documented for S. mansoni that
diagnostic sensitivity depends on the sampling effort, other
helminth species are less well investigated. Repeated or multiple
stool specimen collection is difficult in practice, particularly in
rural community field surveys [20], due to logistical requirements
and cost implications.
The current study pursued two objectives. First, we assessed the
efficacy of two oral PZQ regimens (i.e., 40 mg/kg single dose, and
75 mg/kg divided dose, given as 50 mg/kg then 25 mg/kg
4 hours apart) against S. mekongi and O. viverrini infections.
Second, we determined the effect of multiple stool sampling on
the diagnostic accuracy of the Kato-Katz technique before and
after treatment, and assessed its impact on drug efficacy eva-
luation, considering both cure and egg reduction rates.
Methods
Ethics Statement
Ethical clearance was obtained from the National Ethics
Committee, Ministry of Health (MoH) in Vientiane, Lao PDR
(reference no. 027/NECHR) and by the Ethics Committee of
Basel, Switzerland (EKBB; reference no. 255/06). The study
protocol is registered with Current Controlled Trials on
controlled-trials.com (identifier ISRCTN57714676). Written in-
formed consent was obtained by the parents or guardians of all
pupils before participation in the study. The children had the
opportunity to withdraw from the study at any time.
Both doses of PZQ (i.e., single 40 mg/kg dose or total of
75 mg/kg dose) are accepted within LaoMoH published guidelines.
The 40 mg/kg single dose is mainly used in mass drug adminis-
tration programs, while 75 mg/kg (divided into three dosages) is
used for the treatment of individuals. In our study the 75 mg/kg
dose was divided into two doses (50 mg/kg plus 25 mg/kg given
4 hours apart) to simplify the regimen for a school setting where
classes ended by the early afternoon. At the end of the follow-up
period, all children were treated against soil-transmitted helminth
infections with a single oral dose of 400 mg albendazole [3].
Study Outcomes
The primary objective of this study was to compare the efficacy
of two different dose regimens of oral PZQ in school-aged children
from southern Lao PDR in a S. mekongi and O. viverrini co-endemic
area. The two regimens compared were (i) 40 mg/kg single dose
and (ii) 75 mg/kg divided dose, given as 50 mg/kg then 25 mg/kg
4 hours apart. The secondary objectives were to determine the
effect of multiple stool sampling to assess cure and egg reduction
rates and to estimate the increased diagnostic sensitivity by mul-
tiple Kato-Katz thick smears from a single stool specimen
compared with additional stool specimens obtained over several
days before and after treatment. S. mekongi and O. viverrini were the
species of primary interest, but hookworm was also included for
the baseline analyses. Finally, the prevalence of the other intestinal
helminth infections among our cohort of schoolchildren was also
assessed.
Study Design, Sample Size Calculation, and Population
The dose comparison study was a randomized trial with 1:1
allocation. It was conducted in February and March 2007 in the
primary and secondary schools on Don Long Island, Khong
Author Summary
Parasitic worm infections are of public health importance
in Southeast Asia. Particularly, the blood-dwelling Schisto-
soma mekongi worm, which is acquired by skin contact
with the infectious cercariae in freshwater, can lead to liver
enlargement. An infection with Opisthorchis viverrini is
obtained by consumption of undercooked freshwater fish,
and this infection increases the risk of developing
cholangiocarcinoma. A single oral dose of 40 mg/kg
praziquantel is recommended for mass treatment of
schistosomiasis and opisthorchiasis, while at the individual
level, a total dose of 75 mg/kg divided into three doses, is
currently common practice to treat O. viverrini infection.
Diagnosis is based on stool examination under a micro-
scope for detection of worm eggs, but is limited by the
low sensitivity of the widely used Kato-Katz technique. In
this study, we showed that a 75 mg/kg total dose of
praziquantel (50 mg/kg+25 mg/kg given 4 hours apart)
cleared significantly more O. viverrini infections than a
single 40 mg/kg dose, but no difference was observed for
S. mekongi. Solicited adverse event profiles were mainly
mild and similar in both groups. Repeated stool examina-
tion before and after treatment was essential for an
accurate assessment of drug efficacy in terms of cure rate,
but showed no effect on assessing egg reduction rates.
S. mekongi and O. viverrini: PZQ Dose Comparison
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district, Champasack province, Lao PDR. The 308 children re-
gistered at the Don Long school were invited for the dose
comparison trial. Most of the pupils (60%) lived in one of the four
villages of Don Long Island, whereas the remaining children
traveled from four villages on surrounding islands. In-depth stool
examination was limited to 93 children aged 10–15 years (two
classes). Based on the asymptotic normal method (formula 7) of
Sahai and Khurshid [23], this sample size has a 70% power to
demonstrate a superiority of 20% of the highest PZQ dosage (type
I error: alpha= 5%; 1-tailed test) when considering a 20% dropout
rate. Analyses of the present paper are restricted to this in-depth
cohort. Acutely ill or febrile children were excluded from the
study.
Don Long is a rural island in the Mekong River with about
1,500 inhabitants who practice subsistence farming and fishing.
Previous studies on this island found the area to be co-endemic for
S. mekongi and O. viverrini infections [24,25]. Laboratory facilities
were established in Khong district hospital in Muang Khong, a
village on the east side of Don Khong, the main island of Khong
district.
Treatment: Allocation, Randomization, Dose Preparation,
and Blinding
The children were assigned into two treatment arms following a
1:1 allocation regardless of the baseline examination. Randomi-
zation was generated using a random number table in blocks of 10.
Randomization and supervision of the trial were conducted by the
study leaders (LL, TKM). Based on the child’s weight, the dose
was rounded to the nearest 150 mg by splitting the 600 mg PZQ
tablets (DistocideH, Korea) in quarters using a pill cutter. Doses
were prepared in advance by team members not involved in
administrating the intervention. Each preparation was double
verified for name, dose, and recorded weight for each child.
Twelve hours before treatment, all doses were prepared and sealed
in opaque envelopes that were labeled with the dose number,
study unique identification number, the child’s name, and weight.
After the dose envelopes were prepared, the randomization and
allocation list was sealed in an opaque envelope. Box 1 contained
the envelopes with the first (and only) dose for children allocated in
the 40 mg/kg arm and the first dose for those assigned to the
75 mg/kg arm, organized by school class and name. Box 2
contained the prepared envelopes for the second dose (25 mg/kg)
only for those children allocated for the total dose of 75 mg/kg
PZQ.
The drugs were administered by one of two paired teams of
health care workers. The team confirmed that the child matched
the identification on the drug envelope and then directly observed
treatment. The drug administering teams were not involved prior
to or after the study and not in any outcome assessments. As the
different regimen was apparent (single vs. a divided dose 4 hours
apart) neither the two health care teams nor the children were
masked during treatment administration. The Lao physicians who
assessed the children for adverse events following treatment were
unaware of the dose allocation and were not involved with
administering the intervention (KP, PAS). Laboratory technicians
assessing infection status were blinded to the dose allocation.
Study Procedures
The purpose and procedures of the study were explained to the
school director, teachers, and to the village chief, who all agreed to
participate. The study was explained during class to the children
and written informed consent was received from their parents or
guardians.
Clinical baseline measurements and baseline laboratory deter-
mination of infection status were performed prior to treatment
for each participating child. Clinical measurements included a
morbidity questionnaire and physical examination. For laboratory
procedures, plastic bags with pre-labeled 30 ml plastic containers
were distributed to the children at enrolment and pupils were
asked to return the containers the following day with a thumb-
sized portion of their morning stools. Containers were collected
each morning at the school from 07:30 to 08:30 hours, recorded
on a line listing, and children were given new empty plastic
containers for the following day. This procedure was repeated
until 3 morning stool specimens per child were received. Fresh
stool specimens were transferred daily to the laboratory on Khong
Island for examination. From each stool specimens, triplicate
Kato-Katz thick smears using standard 41.7 mg templates were
prepared on microscope slides in accordance with the kit in-
structions (Vestergaard Frandsen; Lausanne, Switzerland). The
slides were quantitatively examined under a microscope within
1 hour following slide preparation. The number of eggs of O.
viverrini, S. mekongi, hookworm, Trichuris trichiura, Ascaris lumbricoides,
Taenia spp., Enterobius vermicularis, and other helminths were
counted and recorded separately. For quality control, 10% of
the slides were randomly selected and re-examined by a senior
technician without prior knowledge of the results. When discrep-
ancies were observed (e.g., egg counts differing by more than
10%), the technicians received closer supervision by a more
experienced colleague. Since O. viverrini cannot be easily distin-
guished from minute intestinal flukes (MIF) microscopically by the
Kato-Katz technique [26], infections reported here as O. viverrini
infections are assumed to include some MIF co-infections.
Following baseline data collection, children were treated with
40 mg/kg or 75 mg/kg oral PZQ as described. Immediately
following the dose, the children were given two soupspoons of
sticky rice (,40 g) to increase PZQ bioavailability and minimize
potential adverse events [27]. Adverse events spontaneously
reported within 3 hours after administration of the first dose were
recorded. Additionally, a solicited questionnaire on adverse events
was administered 24 hours following PZQ administration and
graded for severity. All clinical and laboratory assessments were
repeated 28–30 days after PZQ administration.
Statistical Analysis
Data were entered in EpiData software version 3.1 (EpiData
Association; Odense, Denmark) and double-checked against the
original data sheets. Data analysis was performed using Inter-
cooled STATA release 9.0 (StataCorp; College Station, TX,
USA).
For each helminth species, an infection was defined as the
presence of one or more eggs in at least one of the Kato-Katz thick
smears examined. Cumulative prevalence of each helminth
infection detected after examination of 9 Kato-Katz thick smears
(3 stool specimens with triplicate Kato-Katz per specimen) was
calculated. Tests for significant associations with gender were
analyzed by negative binomial regression. Intensity of infection
(expressed in EPG) was calculated by multiplying the observed
number of eggs by a factor of 24. Geometric mean intensity of
infection was calculated on EPG. Infections with O. viverrini were
classified into three groups [28]: light (1–999 EPG), moderate
(1,000–9,999 EPG), and heavy infections ($10,000 EPG). S.
mekongi infections were grouped into the following three categories
[29]: light (1–99 EPG), moderate (100–399 EPG), and heavy
infections ($400 EPG). Negative binomial regression was applied
to compare infection intensities of S. mekongi and O. viverrini at
baseline among the two treatment groups.
S. mekongi and O. viverrini: PZQ Dose Comparison
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Cure rates of S. mekongi and O. viverrini were calculated as the
proportion of children with no egg excretion after treatment
among those with eggs in their stool at baseline. Children found
egg-negative prior to treatment but egg-positive after treatment
were considered to be false negative and counted as infected at
baseline. These infections were assumed to have been missed at
baseline because the 28–30 days follow-up would not have
provided adequate time for re-infection and patency between the
two surveys. Cure rates obtained with the two tested doses were
compared with Fisher’s exact test. Egg reduction rates were
determined by comparing the geometric mean egg output before
and 28–30 days after treatment among children infected at
baseline (1 - geometric mean egg output posttreatment/geometric
mean egg output at baseline, multiplied by 100).
The effect of multiple sampling on the sensitivity of the Kato-
Katz technique to detect S. mekongi and O. viverrini infections was
assessed before and after drug administration. Hookworm infec-
tions were also included at baseline. Prevalences with 95%
confidence interval (CI) were calculated for each sampling effort,
the minimum effort being defined as the first Kato-Katz thick
smear derived from the first stool specimen. The sampling effort
increased with additional Kato-Katz thick smear examinations
from the same stool specimen and with additional stool specimens.
The McNemar test was used to compare prevalences assessed by
different sampling efforts. The maximum sampling effort, 9 Kato-
Katz thick smears, was taken as the diagnostic ‘gold’ standard to
assess the sensitivity of increasing sampling efforts.
Adverse event frequencies depending on treatment doses were
compared with the exact x2 test. Additionally, infection intensities
were expressed in EPG and for each child the arithmetic means
were computed for each sampling effort. At the cohort level,
geometric mean fecal egg counts were calculated for each
sampling effort considering only the children with complete
datasets at each time point separately. The analysis was restricted
to the egg-positive children, based on the examination of 9 Kato-
Katz thick smears (maximum sampling effort).
Results
The 93 children (54 boys, 39 girls) included in the in-depth
cohort all agreed to participate and written parental or guardian
consent was received. Participants had a median age of 12 years
(range: 10–15 years). Eighty-five children provided at least one
stool specimen during the baseline survey and during the 28–30
day posttreatment follow-up. Among them, 64 children provided
three stool specimens at both time points and had therefore
complete datasets, with a compliance of 69% (64/93) (see Figure 1).
All schoolchildren were given treatment, according to their
randomized treatment allocation. In the in-depth cohort, 46
children received 40 mg/kg PZQ and 47 received 75 mg/kg
divided dose. The effect of multiple sampling on the sensitivity of
the Kato-Katz technique was analyzed before and after treatment
and was restricted to children with complete datasets at each time
point separately, with a compliance of 97% (90/93) at baseline and
71% (66/93) at the 28–30 day posttreatment follow-up. There
were no significant differences in the gender ratio, average age, or
infection prevalence between the baseline and the posttreatment
follow-up groups (all P.0.05).
Helminth Infection at Baseline
Table 1 summarizes baseline infection prevalences and inten-
sities of all helminth species diagnosed in the present study before
PZQ administration. Results pertained to those children who had
complete data records (9 Kato-Katz thick smears) prior to
treatment (n=90) and before and after treatment combined
(n=64). S. mekongi, O. viverrini, and hookworm were the most
common parasitic infections at baseline, with prevalences above
85% for each helminth species, as assessed with the maximum
sampling effort. Other intestinal parasitic infections, in descending
order of prevalence, were T. trichiura, A. lumbricoides, E. vermicularis,
and Taenia spp. One infection with Hymenolepis diminuta was
detected. Infection prevalences for any of the aforementioned
helminths did not differ between boys and girls.
Praziquantel Cure and Egg Reduction Rates against S.
mekongi and O. viverrini
Cure and egg reduction rates were compared between two
cohorts (Figures 1a and 1b). First, children who complied with the
maximum diagnostic effort (9 Kato-Katz thick smears before and
after treatment, n=64) and, second, children with a minimum
diagnostic effort (1 Kato-Katz thick smear at each time point,
n=85). Results are summarized in Tables 2 and 3. For both
cohorts, there was no significant differences in the infection
intensities of S. mekongi and O. viverrini at baseline between the two
treatment groups (all P.0.05).
S. mekongi cure rates among children who had provided three
stool specimens at baseline and follow-up were 80.8% (21/26;
95% CI: 60.6–93.4%) after 75 mg/kg PZQ and 75.0% (24/32;
95% CI: 56.6–88.5%) after 40 mg/kg PZQ, which was not
significantly different (P=0.754). With the minimum diagnostic
effort, observed cure rates were considerably higher, 94.7% (18/
19; 95% CI: not defined) and 85.7% (18/21; 95% CI: not
defined), respectively. S. mekongi egg reduction rates in both cohorts
were .93%. Slightly higher egg reduction rates were observed at
the minimum sampling effort (97.9% and 99.6% in the 40 mg/kg
and 75 mg/kg treatment group, respectively), compared to the
highest sampling effort (96.4% and 98.1%, respectively).
Based on the maximum sampling effort, O. viverrini cure rates
were 96.6% (28/29; 95% CI: not defined) after 75 mg/kg PZQ
and 71.4% (25/35; 95% CI: 53.4–84.4%) after 40 mg/kg PZQ,
showing a statistically significant difference (P=0.009). Consider-
ing the minimum diagnostic effort, observed cure rates were 100%
(35/35; 95% CI: not defined) and 94.3% (33/35; 95% CI: not
defined), respectively, with no statistically significant difference
(P=0.493). Egg reduction rates, regardless of treatment group and
diagnostic efforts, were above 99%.
Adverse Events
Solicited 24-hour adverse event profiles in the two treatment
groups are summarized in Table 4. Fourteen children were
not available to be interviewed (n= 6, 40 mg/kg dose; n= 8,
75 mg/kg dose), corresponding to 15.1% lost to follow-up, but
no serious adverse events were reported by the community
when we returned days 28–30 for post-treatment follow-up.
Most children reported one or more adverse events (76/79,
96%). More cases were reported for most types of adverse
events in the 75 mg/kg treatment arm, but did not reach
statistical significance in this small sample when comparing the
total number of events or those graded as severe. There were a
total of 7 cases recorded as hypotension (below 100 mm Hg
systolic blood pressure) in the 75 mg/kg treatment group
compared with a single case in the 40 mg/kg group, which was
statistically higher (P,0.02) but no case was graded severe
(e.g., no syncope). Children with hypotension associated with
dizziness and vomiting were given rest and monitored; all cases
were self-limiting. No serious adverse events required hospi-
talization.
S. mekongi and O. viverrini: PZQ Dose Comparison
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Effect of Multiple Sampling Efforts on Cumulative
Prevalence
Figure 2 shows the cumulative prevalence of infected children
over repeated stool specimens according to the number of Kato-
Katz thick smears examined per stool specimen for S. mekongi and
O. viverrini infections both at baseline and at the 28–30 day
posttreatment follow-up survey. Baseline results for hookworm
infections were also recorded although not the primary outcome of
the study (nor were hypotheses made on the efficacy of PZQ
against this helminth species). The sensitivity of three different
Figure 1. Flowchart of subjects with cure and egg reduction rates. Cure and egg reduction rates are presented for O. viverrini and S. mekongi
infections following 40 mg/kg and 75 mg/kg (50 mg/kg+25 mg/kg 4 hours apart) PZQ treatment considering (a) the maximum sampling effort (363,
3 stool specimens with triplicate Kato-Katz thick smears per specimen); (b) the minimum sampling effort (161, single Kato-Katz thick smear from the
first stool specimen).
doi:10.1371/journal.pntd.0001726.g001
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sampling efforts (considering the maximum diagnostic effort of
9 Kato-Katz thick smears as the diagnostic ‘gold’ standard) is
presented in Table 5.
At baseline. Baseline prevalence of S. mekongi infection in-
creased more than two-fold when assessed with the maximal
sampling effort (87.8%; 95% CI: 79.2–93.7%) compared with the
minimal sampling effort (40.0%; 95% CI: 29.8–50.9%), suggesting
a sensitivity of the first Kato-Katz thick smear of 45.6% (95% CI:
34.3–57.2%). By contrast, baseline prevalences of O. viverrini and
hookworm infections assessed with the minimum sampling effort
were already very high (82.2%, 95% CI: 72.7–89.5%; and 81.1%,
95% CI: 71.5–88.6%, respectively), and reached 98.9% (95% CI:
not defined) and 96.7% (95% CI: not defined) when assessed with
the maximum sampling effort. Hence, corresponding sensitivities
of the first Kato-Katz thick smear were 83.1% (95% CI: 73.7–
90.2%) and 83.9% (95% CI: 74.5–90.9%), respectively. For all
three helminth species, examination of triplicate Kato-Katz thick
smears from the first stool specimen (163 sampling scheme) or
examination of one Kato-Katz thick smear per stool specimen
over three specimens (361) led to substantial increases in the
cumulative prevalence estimate in comparison with a single Kato-
Katz thick smear (P,0.01).
The baseline prevalence for S. mekongi infection, as assessed by
three stool specimens , each subjected to a single Kato-Katz thick
smear (361), was 72.2% (95% CI: 61.8–81.1%). This was
significantly higher than a single stool specimen examined by
triplicate Kato-Katz thick smears (163) revealing a prevalence of
60.0% (95% CI: 49.1–70.2%; P=0.028).
For hookworm detection, the prevalence slightly increased from
88.9% (95% CI: 80.5–94.5%) to 94.4% (95% CI: 87.5–98.2%,
P= 0.059). No difference was found for O. viverrini infection preva-
lence comparing the two different sampling schemes (93.3%; 95%
CI: 86.1–97.5% in both cases).
28–30 days after treatment. After PZQ treatment, the
effect of stool sampling effort showed a stronger relative increase in
detecting helminth infections than at the pretreatment baseline
survey. Figures 2 and 3 show that the S. mekongi infection
prevalence rose seven-fold from 3.0% (95% CI: not defined) to
21.2% (95% CI: 12.1–33.0%), and the O. viverrini infection
prevalence showed over a five-fold increase from 3.0% (95% CI:
not defined) to 16.7% (95% CI: 8.6–27.9%), when comparing
results from minimum and maximum sampling efforts. The
sensitivity of a single Kato-Katz thick smear (161) was only 14.3%
(95% CI: not defined) and 18.2% (95% CI: not defined) for S.
Table 1. Baseline prevalence of infection of the main helminth species and infection intensity among egg-positive children.
Full 363 data at baseline (n=90)
Full 363 data at baseline and 28–30 days posttreatment
follow-up (n=64)
Helminth
species Prevalence (%) 95% CI
Infection in-
tensity (EPG) 95% CI Prevalence (%) 95% CI
Infection in-
tensity (EPG) 95% CI
S. mekongi 87.8 79.2–93.7 25 18–33 85.9 75.0–93.4 28 20–40
O. viverrini 98.9 n.d. 342 229–510 98.4 n.d. 337 201–566
Hookworm 96.7 n.d. 321 221–464 95.3 n.d. 252 157–403
T. trichiura 23.3 15.1–33.4 13 7–24 18.8 10.1–30.5 9 4–21
A. lumbricoides 7.8 3.2–15.4 124 9–1,506 6.3 n.d. 16 1–141
E. vermicularis 7.8 3.2–15.4 12 2–53 6.3 n.d. 10 0–242
Taenia spp. 6.7 2.5–13.9 6 2–17 4.7 n.d. 9 0–112
Study was carried out among 93 children in primary and secondary schools on Don Long Island, Khong district, Champasack province, Lao PDR in February and March
2007. Full 363 data refers to children who provided 3 stool specimens over consecutive days, with triplicate Kato-Katz thick smear examinations per stool specimen.
CI, confidence interval; EPG, eggs per gram of stool; n.d., not defined.
doi:10.1371/journal.pntd.0001726.t001
Table 2. S. mekongi infection intensity before (D0) and posttreatment (D28) and egg reduction rate for maximum and minimum
diagnostic effort.
Treatment Maximum diagnostic effort (363 datasets, n=64) Minimum diagnostic effort (161 datasets, n=85)
Infection
intensity n # cured % cured
D0 GM
(EPG)
D28 GM
(EPG) ERR (%) n # cured % cured
D0 GM
(EPG)
D28 GM
(EPG) ERR (%)
40 mg/kg All infections 32 24 75.0 21.0 0.75 96.4 21 18 85.7 47.6 1.00 97.9
1–99 EPG 27 20 74.1 13.1 0.81 93.8 16 13 81.3 22.4 1.48 93.4
100–399 EPG 3 3 100 157.1 0 100 2 2 100 200.8 0 100
$400 EPG 2 1 50.0 451.3 1.52 99.7 3 3 100 923.0 0 100
75 mg/kg All infections 26 21 80.8 26.6 0.52 98.1 19 18 94.7 63.5 0.23 99.6
1–99 EPG 22 17 77.3 18.2 0.64 96.5 14 13 92.9 45.1 0.32 99.3
100–399 EPG 4 4 100 201.7 0 100 5 5 100 163.6 0 100
$400 EPG 0 0 na na na na 0 0 na na na na
EPG, eggs per gram of stool; ERR, egg reduction rate; GM, geometric mean; na, not applicable.
doi:10.1371/journal.pntd.0001726.t002
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mekongi and O. viverrini, respectively (Table 5). Similar to baseline, a
361 sampling effort led to a moderately higher sensitivity than a
163 sampling effort (P=0.059) to detect S. mekongi eggs, but there
was no significant difference in sensitivity to detect O. viverrini eggs.
Effect of Multiple Sampling Efforts on Mean Fecal Egg
Counts
Figure 3 illustrates the results of increased sampling effort on the
geometric mean fecal egg counts before and after PZQ treatment
of all children infected with S. mekongi and O. viverrini. This was also
assessed for hookworm at baseline.
At baseline, the mean fecal egg counts gradually increased
with increasing sampling efforts. Thus, egg count estimates for S.
mekongi, O. viverrini, and hookworm increased 4, 2.4 and 1.7-fold,
reaching values of 25 EPG, 342 EPG and 321 EPG, respectively,
when assessed with the maximum sampling effort. S. mekongi and
O. viverrini mean fecal egg count estimates were considered low-
intensity infections.
After PZQ treatment, the benefit of the maximum sampling
effort for EPG was 9-fold and 8-fold for S. mekongi and O. viverrini,
respectively. When comparing the pretreatment baseline with the
28–30 day posttreatment follow-up, the mean fecal egg count for
Table 4. Solicited adverse events reported 24 hours following PZQ administration (n= 93).
Total no. of reports Reports graded as severe
Organ class Symptoms 40 mg/kg 75 mg/kg p* 40 mg/kg 75 mg/kg p*
(n=40) (n=39) (n=40) (n=39)
Systemic Allergic reaction 1 0 0.32 0 0
Fever 0 2 0.15 0 0
Headache 27 31 0.23 0 0
Anxiety 1 2 0.54 0 0
Fatigue 24 28 0.27 0 0
Vertigo/dizziness 20 23 0.42 0 1 0.31
Gastro-intestinal Nausea 9 12 0.41 0 0
Vomiting 5 11 0.08 0 2 0.15
Diarrhea 7 5 0.56 0 0
Constipation 2 0 0.16 0 0
Abdominal pain 23 27 0.28 0 0
Cardiovascular Palpitations 4 6 0.47 0 0
Hypotension 1 7 0.02 0 0
Respiratory Cough 1 1 0.99 0 0
Bronchospasm 1 1 0.99 0 0
Dyspnea 1 1 0.99 0 0
*according to exact x2 test.
The two study groups were 40 mg/kg vs. 75 mg/kg divided into 2 doses of 50 mg/kg+25 mg/kg, 4 hours apart.
doi:10.1371/journal.pntd.0001726.t004
Table 3. O. viverrini infection intensity before (D0) and posttreatment (D28) and egg reduction rate for maximum and minimum
diagnostic effort.
Treatment Maximum diagnostic effort (363 datasets, n=64) Minimum diagnostic effort (161 datasets, n=85)
Infection
intensity n # cured % cured
D0 GM
(EPG)
D28 GM
(EPG) ERR (%) n # cured % cured
D0 GM
(EPG)
D28 GM
(EPG) ERR (%)
40 mg/kg All infections 35 25 71.4 307.4 0.99 99.7 35 33 94.3 411.8 0.26 99.94
1–999 EPG 24 18 75.0 96.4 0.48 99.5 24 24 100 142.3 0 100
1,000–9,999 EPG 9 6 66.7 2,460 2.1 99.92 9 7 77.8 2,817 1.4 99.95
$10,000 EPG 2 1 50.0 27,344 9.0 99.97 2 2 100 23,778 0 100
75 mg/kg All infections 29 28 96.6 308.1 0.05 99.98 35 35 100 383.7 0 100
1–999 EPG 20 20 100 103.7 0.00 100 24 24 100 181.1 0 100
1,000–9,999 EPG 9 8 88.9 3,424.2 0.16 100 10 10 100 1,568 0 100
$10,000 EPG 0 0 na na na na 1 1 100 18,816 0 100
EPG, eggs per gram of stool; ERR, egg reduction rate; GM, geometric mean; na, not applicable.
doi:10.1371/journal.pntd.0001726.t003
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Figure 2. Cumulative prevalence according to the sampling effort. Cumulative infection prevalences for (a) S. mekongi and (b) O. viverrini by
the number over consecutive days of stool specimen collection (x-axis). Each point on a curve represents a cumulative prevalence value for each
sampling effort (number of Kato-Katz thick smears per stool specimen). At baseline (day 0), n= 90; after treatment (days 28–30), n= 66.
doi:10.1371/journal.pntd.0001726.g002
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O. viverrini sharply decreased from 342 to 9.1 EPG. The decrease
was less marked for S. mekongi, from 25 to 8 EPG.
A 361 sampling effort yielded substantially higher estimates
than a 163 sampling effort for S. mekongi and hookworm egg
counts. By contrast, the same efforts showed only a minimal
increase for O. viverrini egg counts.
Discussion
PZQ is the drug of choice against most trematode infections,
including schistosomiasis and opisthorchiasis. To our knowledge,
PZQ dose comparison studies have not been described for S.
mekongi. Dose comparison studies for O. viverrini have been
conducted, but most studies relied on an insensitive diagnostic
approach, i.e., single stool specimen examination before and after
drug administration. The accuracy of diagnosis, which is parti-
cularly important for estimating cure rates, can be improved by
examining multiple Kato-Katz thick smears derived from a single
or multiple stool specimens [30].
In this study, S. mekongi cure rate after administration of 75
mg/kg PZQ (80.8%) was not significantly higher than the cure
rate obtained after a single dose of 40 mg/kg (75.0%) when
assessed with the maximum sampling effort of 9 Kato-Katz thick
smears. The cure rate from either regimen was largely overesti-
mated if diagnosis was based on a single Kato-Katz thick smear.
Studies based on fewer Kato-Katz thick smears are more likely to
overestimate cure rate and be less diagnostically sensitive to detect
any differences in dose comparisons. Two small studies carried out
in the 1980s on S. mekongi infection reported high cure rates with
60 mg/kg PZQ (90.9% and 97.5%, respectively) [5,6] when
analyzing 2–3 stool specimens but using different stool diagnostic
techniques (Kato-Katz+modified Ritchie’s and Stoll’s, respective-
ly). Similarly in a recent multi-country randomized trial compar-
ing single 40 mg/kg and 60 mg/kg PZQ in children aged 10–19
years, with infections diagnosed by two stool specimens (duplicate
Kato-Katz thick smears per specimen), the 21-day posttreatment
follow-up was reported as 92.8% with 60 mg/kg, which was not a
significant improvement against S. mansoni, S. haematobium, or S.
japonicum infections compared to the standard 40 mg/kg [31].
Consistent with results obtained from this recent trial, our study
did not document a significantly improved cure rate (days 28–30
posttreatment) with an even higher total dose (75 mg/kg dose) for
S. mekongi, even with higher diagnostic sensitivity from greater stool
sampling efforts. However our additional sampling effort did
observe a cure rate for 40 mg/kg about 15% lower than rates
reported in the multicenter trial.
O. viverrini cure rate after administration of 75 mg/kg PZQ
(96.6%) was significantly higher than the cure rate obtained after
a single dose of 40 mg/kg (71.4%) when assessed with the
maximum sampling effort. However, if the cure rate had been
based on results of single Kato-Katz thick smear before and after
drug administration, as often the case in community-based sur-
veys, no significant difference would have been found. Cure rate
was particularly overestimated when based on a single Kato-Katz
thick smear in this study for a 40 mg/kg dose (94.3%), similar to
high, and most likely overestimated cure rates (91–100%) reported
from previous studies using the same dosage and only a single stool
examination [9,10,12]. Cure rates which were reported as 100%
after administration of 75 mg/kg PZQ (divided into three doses)
were also likely overestimated in previous studies [7,13].
Our study therefore provides supportive evidence that a
75 mg/kg total dose of PZQ is highly efficacious against O.
viverrini and S. mekongi infections in school-aged children from Lao
PDR. The total dose was divided into two doses instead of three
and had a 24-hour profile of common adverse events similar to a
single 40 mg/kg dose. Two doses, instead of three, are opera-
tionally and logistically more feasible, but clearly single-dose
regimens are the preferred option for large-scale preventive
chemotherapy programs. The small size of our study, however,
limits detecting a difference in the nature or frequency of adverse
events between the two regimens.
The non-significant difference between the two doses to cure S.
mekongi infections should be interpreted with caution. Again, this
may result from the study’s small sample size and it would
therefore be valuable to investigate a larger sample. In addition,
most of the children included in our study only had low intensity
infections while cure rate achieved by PZQ has been shown to be
influenced by the infection burden [32]. Some authors have
argued that egg reduction rate is a more appropriate indicator
than cure rate for drug efficacy evaluation [33,34]. We assessed
both cure and egg reduction rates. Importantly, we found very
high egg reduction rates (.99%) against O. viverrini for both
treatment regimens regardless of the sampling effort. For S.
mekongi, considering 9 Kato-Katz thick smears as the diagnostic
‘gold’ standard, a somewhat lower egg reduction rate was observed
with a single 40 mg/kg dose of PZQ compared to the higher split
dose (96.4% vs. 98.1%). At the lower sampling effort, higher egg
reduction rates were observed (97.9% and 99.6%, respectively).
These data suggest that the worm burden sharply declined from
either dose regimen, which was found using either minimal or
maximal diagnostic effort. This may be explained by the low
Table 5. Sensitivity of different sampling efforts to detect S. mekongi and O. viverrini infections.
Sensitivity of different Kato-Katz thick smear sampling efforts
Helminth species Baseline survey (n=90) Days 28–30 posttreatment follow-up (n=66)
1 stool
1 smear
1 stool
3 smears
3 stools
1 smear
3 stools
3 smears
1 stool
1 smear
1 stool
3 smears
3 stools
1 smear
3 stools
3 smears
n (%) n (%) n (%)
n (‘gold’
standard) n (%) n (%) n (%)
n (‘gold’
standard)
S. mekongi 36 (45.6) 54 (68.4) 65 (82.3) 79 (100) 2 (14.3) 3 (21.4) 8 (57.1) 14 (100)
O. viverrini 74 (83.1) 84 (94.4) 84 (94.4) 89 (100) 2 (18.2) 4 (36.4) 5 (45.4) 11 (100)
Study was carried out among 93 children in primary and secondary schools on Don Long Island, Khong district, Champasack province, Lao PDR in February and March
2007. Sensitivity is compared before (n=90) and after PZQ administration (n=66), using the maximum sampling effort as the diagnostic ‘gold’ standard for the
following sampling efforts: 161 sampling effort examines the first Kato-Katz thick smear only; 163 examines the first stool specimen by triplicate Kato-Katz thick smears;
361 examines 3 stool specimens by a single Kato-Katz thick smear for each specimen.
doi:10.1371/journal.pntd.0001726.t005
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Figure 3. Geometric mean fecal egg counts according to the sampling effort. Geometric mean fecal egg counts before and after PZQ
treatment, by the number of days of stool specimen collection (x-axis), based on children diagnosed ‘‘infected’’ following maximum Kato-Katz thick
smear sampling effort. (a) S. mekongi infected at baseline (day 0), n= 79; days 28–30 after treatment, n=14; and (b) O. viverrini infected at baseline
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posttreatment infection intensity of the non-cured children given
either dose. The geometric mean egg counts in the two PZQ
regimens were very similar. The public health goal of preventive
chemotherapy is to reduce morbidity, which is indirectly assessed
using egg reduction rates. Our results suggest that PZQ, given at a
single oral dose of 40 mg/kg, is suitable to achieve this goal,
particularly against O. viverrini.
At baseline, the relative increase of sensitivity by multiple
sampling was relatively low, especially for O. viverrini and hook-
worm infections. By contrast, multiple sampling was important
after treatment, when infection prevalence and intensity were
much lower. As a result, the sensitivity of the first Kato-Katz thick
smear was much lower after treatment than at baseline, with a
4-fold lower and 3-fold lower sensitivity to detect O. viverrini and S.
mekongi infections, respectively.
A single Kato-Katz thick smear is known to have a low sen-
sitivity for the diagnosis of O. viverrini, especially for low intensity
infections [20]. For S. mekongi, the low sensitivity of a single Kato-
Katz thick smear to detect this fluke observed in the present study
agrees with previous findings obtained from investigations focusing
on S. mansoni and S. japonicum [18,19,22,35,36]. Studies on the
sensitivity of the Kato-Katz technique for diagnosis of S. mekongi
are generally lacking.
For O. viverrini and hookworm diagnosis, the sensitivity of a
single Kato-Katz thick smear to detect infection at baseline was
fairly high. For hookworm, this was in contrast to previous studies
from Coˆte d’Ivoire [37,38], Ethiopia [18], and Tanzania [39],
where the sensitivity of a single Kato-Katz thick smear varied from
18% to 53%. However, after drug administration, when the over-
all O. viverrini infection intensity of our cohort of children became
low (,10 EPG), this study indicates the need for multiple Kato-
Katz thick smear examinations, ideally performed on stool
specimens collected over consecutive days for a more accurate
estimation of the cure rate.
Helminth eggs are non-randomly distributed within a stool
specimen because the intestinal content is not uniformly mixed
[40] and may affect the sensitivity of detecting an infection and
fecal egg count estimates from a single Kato-Katz thick smear.
Important day-to-day variation in egg output has been thoroughly
documented for S. mansoni and S. japonicum [19,21,22,35]. By
contrast, O. viverrini egg output was found to be relatively consistent
over a period of several days in hospitalized patients [41]. Of note,
Schistosoma egg shedding dynamics are additionally affected by
retention of eggs in intestinal and liver tissues and the lower
fecundity of female worms.
We have compared the relative importance of intra-specimen
and day-to-day variation of fecal egg counts before and after PZQ
administration and determined its effect on evaluating anthelmin-
tic drug efficacy. Previous research has shown that the examina-
tion of fewer specimens from different days proved to be superior
than examining multiple Kato-Katz thick smears from a single
stool specimen for more accurate estimates of the ‘true’ infection
status for S. mansoni [19,22]. In the present study for S. mekongi and
hookworm infections, examination of one Kato-Katz thick smear
per stool specimen, with specimens collected over a 3-day period
(361 sampling scheme), resulted in higher prevalence and mean
infection intensity than three Kato-Katz thick smears taken from
the first stool specimen (163). For O. viverrini, however, the 361
and 163 sampling scheme revealed the same prevalence estimates.
Since repeating the collection of a stool specimen over consecutive
days is more costly, logistically more cumbersome, and negatively
impacts on study compliance, examination of multiple Kato-Katz
thick smears from a single stool specimen should be considered as
a suitable approach for community surveys of helminth infections.
Similar observations have been made before for the diagnosis of
Clonorchis sinensis [42].
S. mekongi is known to be endemic in certain areas of the Mekong
River basin [25,43–45], while O. viverrini and hookworm species
are widely distributed across Lao PDR [46–48]. Point prevalences
as high as those observed in the present study for S. mekongi
(87.8%), O. viverrini (98.9%), and hookworm (96.7%), based on a
rigorous diagnostic effort, have rarely been described in the
literature. Yet, our findings corroborate with a recent risk profiling
study in more than 50 villages of Champasack province, where
O. viverrini prevalences were above 80% in most villages, with
particularly high prevalences observed in villages in close
proximity to the Mekong River [24]. WHO surveyed selected
villages on Khong Island (an island also situated along the Me
kong River, only 10 km from our study site) prior to starting
schistosomiasis control campaigns in the late 1980s, and found a
similarly high S. mekongi prevalence (87.8%) as reported here [49].
Studies carried out in rural provinces of southern Lao PDR
(Champasack and Saravane) reported prevalences of O. viverrini
and hookworm ranging from 18.8% to 70.8% and from 12.5% to
46.1%, respectively [46,47,50,51]. Infection prevalence is known
to vary locally [46], which may partially explain the difference
between prior estimates and those found in this study. However,
previous prevalence estimates were based on a single Kato-Katz
thick smear, while 9 Kato-Katz thick smears were examined in the
present study. O. viverrini infection prevalence probably includes
MIF infections since co-infections are common, and polymerase
chain reaction (PCR) techniques on stool specimens taken from
the same study area in southern Lao PDR [52] have demonstrated
that MIF eggs cannot easily be distinguished microscopically from
O. viverrini by the Kato-Katz technique [26].
In conclusion, the present study found that the added benefit of
multiple Kato-Katz thick smear examination and repeated stool
sampling depends on the helminth species and baseline infection
intensity. Thus, in the present setting in Lao PDR, where O.
viverrini, S. mekongi, and hookworm are all highly endemic, esti-
mating the baseline prevalence and intensity of infection for these
species with a single Kato-Katz examination may be acceptable.
By contrast, estimating the prevalence of infection after treatment
by the Kato-Katz technique requires multiple thick smears,
ideally taken from multiple stool specimens because the positive
predictive value is lower (both lower prevalence and lower
geometric mean fecal egg count after treatment). A single Kato-
Katz thick smear after treatment will considerably overestimate
cure rate, but only minimally influences egg reduction rates. A
rigorous diagnosis approach is necessary for estimating ‘true’ cure
rates, as it has been previously demonstrated in studies on S.
mansoni [30,53]. For anthelmintic drug evaluations with emphasis
on egg reduction rates, a single Kato-Katz thick smear before and
after treatment might suffice. In our view, multiple stool ex-
amination should nonetheless be considered in a subsample of the
population surveyed in order to improve the monitoring of large-
scale control programs, provide reasonable estimates on infection
prevalence and intensity, and detect subtle changes in drug
efficacies that might indicate the emergence of drug resistance
development.
(day 0), n= 89; days 28–30 after treatment, n= 11. Each point on a curve represents the geometric mean fecal egg count for each sampling effort
(number of Kato-Katz thick smears examined per stool specimen).
doi:10.1371/journal.pntd.0001726.g003
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